Cytokines in inflammatory bowel disease

Mediators of Inflammation

Volumn 6, Issue 2, 1997, Pages 95-103

  Beck, P L ^a   Wallace, J L ^a  

^a UNIVERSITY OF CALGARY   (Canada)

Author keywords

Crohn's disease; Interferons; Interleukins; Intestine; Tumor necrosis factor; Ulcerative colitis

Indexed keywords

1 [4 [N CHLOROACETYL N (2 ISOPROPOXYETHYL)AMINO]BENZOYL] 4 [2 (4 CHLOROPHENYL)ETHYL]PIPERAZINE; ALPHA INTERFERON; ANTIINFECTIVE AGENT; CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE; CYTOKINE ANTIBODY; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 10; INTERLEUKIN 11; INTERLEUKIN 13; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 8; MESALAZINE; MONOCLONAL ANTIBODY; RAPAMYCIN; SHORT CHAIN FATTY ACID; TACROLIMUS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

B LYMPHOCYTE; CLINICAL TRIAL; CROHN DISEASE; HUMAN; IMMUNE RESPONSE; MEDIATOR; NATURAL KILLER CELL; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; ULCERATIVE COLITIS;

EID: 0030986694     PISSN: 09629351     EISSN: None     Source Type: Journal    
DOI: 10.1080/09629359791785     Document Type: Review

References (86)

1. Cominelli F, Cytokines. In: Wallace JL, ed. Immunopharmacology of the Gastrointestinal System. London: Academic Press, 1993; 123-136.
2. Kam L, Pizarro TT, Cominelli F. Cytokine and chemokines in inflammatory bowel disease. Curr Opin Gastroenterol 1995; 11: 305-309.
3. Sartor RB. Cytokines in intestinal inflammation: pathophysiologic and clinical considerations. Gastroenterology 1994; 106: 533-539.
4. Ligumsky M, Simon PL, Karmeli F, Rachmilewitz D. Role of interleukin 1 in inflammatory bowel disease: enhanced production during active disease. Gut 1990; 31: 686-689.
5. Nishiyama T, Mitsuyama K, Toyonaga A, Sasaki E, Tanikawa K. Colonic mucosal interleukin 1 receptor antagonist in inflammatory bowel disease. Digestion 1994; 55: 368-373.
6. Mazlam MZ, Hodgson HJ. Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease. Gut 1994; 35: 77-83.
7. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, MacDermott RP, Raedler A. Enhanced secretion of tumor necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-181.
8. Casini-Raggi V, Kam L, Chong YJ, Fiocchi C, Pizarro TT, Cominelli F. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation. J Immunol 1995; 154: 2434-2440.
9. Hyams JS, Fitzgerald JE, Wyzga N, Treen WR, Justinich CJ, Kreutzer DL. Characterization of circulating interleukin-1 receptor antagonist expression in children with inflammatory bowel disease. Dig Dis Sci 1994; 39: 1893-1899.
10. McCall RD, Haskill S, Zimmermann EM, Lund FK, Thompson RC, Sartor RB. Tissue interleukin 1 and interleukin 1 receptor antagonist expression in enterocolitis in resistant and susceptible rats. Gastroenterology 1994; 106: 960-972.
11. Cominelli F, Nast CC, Clark BD, Schindler R, Llerena R, Eysselin VE, Thompson RC, Dinarello CA. Interleukin 1 (IL-1) gene expression, synthesis, and effect on specific IL-1 receptor blockade in rabbit immune complex colitis. J Clin Invest 1990; 86: 972-980.
12. McCafferty D-M, Rioux KP, Wallace JL. Granulocyte infiltration in experimental colitis is interleukin-1 dependent and leukotriene independent. Eicosanoids 1992; 5: 121-125.
13. Ferretti M, Casini-Raggi V, Pizarro TT, Eisenberg S, Nast CC, Cominelli F. Neutralization of endogenous IL-1 receptor antagonist exacerbates and prolongs inflammation in rabbit immune colitis. J Clin Invest 1994; 94: 449-453.
14. Sher ME, D'Angelo AJ, Stein TA, Bailey B, Burns G. Cytokines in Crohn's colitis. Am J Surg 1995; 169: 133-136.
15. Gionchetti P, Campieri M, Belluzzi A, Bertinelli E, Ferretti M, Brignola C, Poggioli G, Miglioli M, Barbara L. Mucosal concentrations of interleukin-1 beta, interleukin-6, interleukin-8, and tumor necrosis factor-alpha in pelvic ileal pouches. Dig Dis Sci 1994; 39: 1525-1531.
16. Casini-Raggi V, Monsacchi L, Vosbeck K, Nast CC, Pizarro TT, Cominelli F. Anti-inflammatory effects of CGP 47969A, a novel inhibitor of proinflammatory cytokine synthesis, in rabbit immune colitis. Gastroenterology 1995; 109: 812-818.
17. Pullan RD, Rhodes J, Ganesh S, Mani V, Morris JS, Williams GT, Newcombe RG, Russel MA, Feyerabend C, Thomas GA. Transdermal nicotine for active ulceralive colitis. New Engl J Med 1994; 330: 811-815.
18. Thomas GA, Rhodes J, Mani V, Williams GT, Newcombe RG, Russel MA, Feyerabend C. Transdermal nicotine as maintenance therapy for ulcerative colitis. New Engl J Med 1995; 332: 988-992.
19. Van Dijk JPM, Madretsma GS, Keuskamp ZJ, Zijlstra FJ. Nicotine inhibits cytokine synthesis by mouse colonic mucosa. Eur J Pharmacol 1995; 278: R11-R12.
20. Manzano L, Alvarez-Mon M, Vargas JA, Giron JA, Fernandez-Corugedo A, Roman LI, Albarran F, Durantez A. Deficient interleukin 2 dependent proliferation pathway in T lymphocytes from active and inactive ulcerative colitis patients. Gut 1994; 35: 955-960.
21. Mullin GE, Lazenby AJ, Harris ML, Bayless TM, James SP. Increased interleukin-2 messenger RNA in the intestinal mucosal lesions of Crohn's disease but not ulcerative colitis. Gastroenterology 1992; 102: 1620-1627.
22. Gurbindo C, Sabbah S, Menezes J, Justinich C, Marchand R, Seidman EG. Interleukin-2 production in pediatric inflammatory bowel disease: evidence for dissimilar mononuclear function in Crohn's disease and ulcerative colitis. J Ped Gastroenterol Nutr 1993; 17: 247-254.
23. Sparano JA, Brandt LJ, Dutcher JP, DuBois JS, Atkins MB. Symptomatic exacerbation of Crohn's disease after treatment with high dose interleukin-2. Ann Int Med 1993; 118: 617-618.
24. Brynskov J, Freund J, Norby Rasmussen S, et al. Final report on a placebo controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active Crohn's disease. Scand Gastroenterol 1991; 26: 689-695.
25. Lichtiger S, Present DH, Kornbluth A, Gelernt I, Bauer J, Galler G, Michelassi F, Hanauer S. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. New Engl J Med 1994; 330: 1841-1845.
26. Aiko S, Grisham MB. Effects of Cyclosporine of FK506 on pathophysiology observed in a model of chronic granulomatous colitis in rats. Gastroenterology 1995; 108: A768 (abstract).
27. Dubucquoi S, Janin A, Klein O, Desreumaux P, Quandalle P, Cortot A, Capron M, Colombel J-F. Activated eosinophils and interleukin 5 expression in early recurrence of Crohn's disease. Gut 1995; 37: 242-246.
28. Stevceva L, Pavli P, Matthei K, Yound I, Doe WF. Dextran sulphate sodium-induced colitis develops in IL-5 knockout mice. Gastroenterology 1995; 108: A922 (abstract).
29. Baumann H, Gauldie J. The acute phase response. Immunol Today 1994; 15: 74-80.
30. Patel RT, Bain I, Youngs D, Keighly MR. Cytokine production in pouchitis is similar to that in ulcerative colitis. Dis Colon Rectum 1995; 38: 831-837.
31. Holtkamp W, Stollberg T, Reis HE. Serum interleukin-6 is related to disease activity but not specificity in inflammatory bowel disease. J Clin Gastroenterol 1995; 20: 123-126.
32. Mitsuyama K, Toyonaga A, Sasaki E, Ishida O, Ikeda H, Tsuruta O, Harada K, Tateishi H, Nishiyama T, Tanikawa K. Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995; 36: 45-49.
33. Louis E, Belaiche J, Van Kemseke C, DeGroote D. Crohn's disease relapse prediction by interleukin-6 serum level. Gastroenterology 1995; 108: A865 (abstract).
34. Mitsuyama K, Toyonaga A, Sasaki E, Watanabe K, Tateishi H, Nishirama T. Saiki T, Ikeda H, Tsudruta O, Tanikawa K. IL-8 as an important chemoattractant for neutrophils in ulcerative colitis and Crohn's disease. Clin Exp Immunol 1994; 96: 432-436.
35. Gibson P. Rosella O. Interleukin-8 secretion by colonic crypt cells in vitro: response to injury suppressed by butyrate and enhanced in inflammatory bowel disease. Gut 1995; 37: 536-543.
36. Casellas F, Papo M, Guarner F, Antolin M, Armengol JR, Malagelada JR. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis. Clin Sci 1994; 87: 453-458.
37. 2 from activated eosinophils and macrophages in ulcerative colitis. Am J Gastroenterol 1995; 90: 614-620.
38. Autschbach F, Schurmann G, Quio L, Merz H, Wallich R, Meuer SC. Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease. Virchow's Archiv 1995; 426: 51-60.
39. Hudson M, Gallati H, Ryff JC, Pounder RE, Wakefield AJ. Serum tumour necrosis factor (TNF) and soluble TNF receptors p55 and p75 in Crohn's disease. Gastroenterology 1993; 104: A715 (abstract).
40. Hadziselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut 1995; 37: 260-263.
41. Van Dullemen HM, Van Deveter SJH, Hommes DW, Bijl HA, Jansen J, Tytgat GNJ, Wood J. Treatment of Crohn's disease with anti-tumour necrosis factor chimeric antibody (cA2). Gastroenterology 1995; 109: 129-135.
42. Plevy SE, Carramanzana NM, Deem RL, Woody JN, Targan SR. Clinical improvement in Crohn's diseuse patients treated with anti-TNFα correlates with downregulated mucosal T helper 1 responses. Gastroenterology 1996; 110: A993 (abstract).
43. 1 anti-TNFα antibody in Crohn's disease. Gastroenterology 1996; 110: A1018 (abstract).
44. McCabe RP, Woody J, van Deveter S, Targan SR, Mayer L, van Hogezand R, Rutgeerts P, Hanauer SB, Podolsky D, Elson CO. A multicenter trial of cA2 anti-JNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 1996; 110: A962 (abstract).
45. Sands BE, Podolsky DK, Tremaine WJ, Sanborn WJ, Rutgeerts PJ, Hanauer SB, Mayer L, Targan SR, DeWoody KL, Braakman TAJ, Woody JN. Chimeric monoclonal anti-tumor necrosis factor antibody cA2 in the treatment of severe, steroid-refractory ulcerative colitis. Gastroenterology 1996; 110: A1008 (abstract).
46. Baert F, D'Haens G, Geboes K, Ectors N, Rutgeerts P. TNF-α antibody therapy causes a last and dramatic decrease of histological colonic inflammation in Crohn's disease but not in ulcerative colitis. Gastroenterology 1996; 110: A859 (abstract).
47. Elliot MJ, Maini RN, Feldmann M, Kalden JR, Antoni C, Smolen JS, Leeb B, Breedveld FC, Macfarlane JD, Bijl H, Woody JN. Randomized double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-1110.
48. Fais S, Capobiachi MR, Silvestri M, Mercuri F, Pallone F, Dianzani F. Interferon expression in Crohn's disease patients: increased interferon-gamma and alpha mRNA in the intestinal lamina propria mononuclear cells. J Interferon Res 1994; 14: 235-238.
49. Davidsen B, Munkholm P, Schlichting P, Nielsen OH, Krarup H, Bonnevie-Nielsen V. Tolerability of interferon alpha-2b, a possible new treatment of active Crohn's disease. Aliment Pharm Therap 1995; 9: 75-79.
50. Gasche C, Reinisch W, Vogelsang H, Potzi R, Markis E, Micksche M, Wirth HP, Gangl A, Lochs H. Prospective evaluation of interferon-alpha in treatment of chronic active Crohn's disease. Dig Dis Sci 1995; 40: 800-804.
51. Schreiber S, Heinig T, Panzer U, Reinking R, Bouchard A, Stahl PD, Raedler A. Impaired response of activated mononuclear phagocytes to interleukin 4 in inflammatory bowel disease. Gastroenterology 1995; 108: 21-33.
52. Karttrunnen R, Breese EJ, Walker-Smith JA, MacDonald TT. Decreased mucosal interleukin-4 (IL-4) production in gut inflammation. J Clin Pathol 1994; 47: 1015-1018.
53. Kucharzik T, Stoll R, Lugering N, Domschke W. Circulating antiinflammatory IL-10 in patients with inflammatory bowel disease (IBD). Clin Exp Immunol 1995; 100: 452-456.
54. Kühn R, Löhler J, Rennick D, Rajewsky K, Müller W. Interleukin-10 deficient mice develop chronic enterocolitis. Cell 1993; 75: 263-274.
55. Schreiber S, Heinig T, Thiele HG, Raedler A. Immunoregulatory role of interleukin 10 in patients with inflammatory bowel disease. Gastroenterology 1995; 108: 1434-1444.
56. Del Prete G, De Carli M, Amerigogna F, Giudizi MG, Biagotti R, Romagnini S. Human IL-10 is produced by both type 1 (Th 1) and type 2 helper (Th 2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 1993; 150: 353-360.
57. Ribbons KA, Eloby-Childress S, Thompson J, Zhang XJ, Pennline K, Miller MJS. Effect of interleukin-10 in TNBS-induced colitis in rats. Gastroenterology 1996; 110: A11001.
58. Grool TA, Meenan J, Van Dulleman H, Koster F, Ten Kate FJW, Lebeaut A, Tytgat GNJ, Van Deventer SJH. The anti-inflammatory effect of interleukin 10 in a rabbit model of immune complex-induced colitis. Gastroenterology 1996; 110: A918.
59. Herfarth H, Janardhanam R, Rath HC, Sartor RB. In vivo IL-10 treatment suppresses experimental chronic granulomatous inflammation and has an additive effect with corticosteroids. Gastroenterology 1996; 110: A924.
60. Madsen KL, Tavernini MM, Fedorak RN. Interleukin-10 modulates ion transport in rat small intestine. Gastroenterology 1996; 111: 936-944.
61. Kobayashi S, Teramura M, Oshimi K, Mizoguchi H. Interleukin-11. Leukemia Lymphoma 1994; 17: 45-49.
62. Neben S, Turner K. The biology of interleukin-11. Stem Cells 1993; 11 (suppl 2): 156-162.
63. Potten CS. Interleukin-1 protects to clonogenic stem cells in murine small-intestinal crypt from impairment of their reproductive capacity by radiation. Int J Cancer 1995; 62: 356-361.
64. Du XX, Doerschuk CM, Orazi A, Williams DA. A bone marrow stromal-derived growth factor, interleukin-11, stimulates recovery of small intestinal mucosal cells after cytoablative therapy. Blood 1991; 83: 33-37.
65. Castagliuolo I, LaMont JT, Baker C, Nikulasson ST, Keith JC, Pothoulakis C. Recombinant human interleukin-11 (rhIL-11) inhibits Clostridium difficile toxin A-mediated enterotoxicity in rat ileum. Gastroenterology 1995; 108: A792 (abstract).
66. Albert LM, Ferranti TJ, Erickson JE, Donnelly LH, Schaub RG, Keith JC. Dose response and schedule studies of recombinant human interleukin-11 in acetic acid induced colonic injury in rats. Gastroenterology 1995; 108: A768 (abstract).
67. Keith JC, Albert LM, Ferranti TJ, Erickson JE, Mason LE, Donnelly LH, Misra BR, Schaub RG. Recombinant human interleukin-11 (rhIL-11) decreases inflammatory bowel disease in HLA-B27 transgenic rats. Gastroenterology 1995; 108: A846 (abstract).
68. Qiu B, Pfeiffer CJ. Protection by recombinant human interleukin-11 against experimental TNBS-induced colitis in rats. Dig Dis Sci 1996; 41: 1625-1630.
69. Yano S, Sone S, Nishioka Y, Mukaida N, Matsushima K, Ogura T. Differential effects of anti-inflammatory cytokine (IL-4, IL-10, IL-13) on tumoricidal and chemotactic properties of human monocytes induced by monocyte chemotactic and activating factor. J Leuk Biol 1995; 57: 303-309.
70. Onoe Y, Miyaura C, Kaminakayashiki T, Nagai Y, Noguchi K, Chen QR, Seo H, Ohta H, Nozawa S, Kudo I, Suda T. IL-13 and IL-4 inhibit bone reabsorption by suppressing cyclooxygenase-2-dependent prostaglandin synthesis in osteoblasts. J Immunol 1996; 156: 758-764.
71. Kim C, Schinkel C, Fuchs D, Satdler J, Walz A, Zedler S, von Donnersmarck GH, Faist E. Interleukin-13 effectively down-regulates the monocyte inflammatory potential during traumatic stress. Arch Surg 1995; 130: 1330-1336.
72. Bochner BS, Klunk DA, Sterbinsky SA, Coffman RL, Schleimer RP. IL-13 selectively induces vascular cell adhesion molecule-1 expression in human endothelial cells. J Immunol 1995; 154: 799-803.
73. Schlaak JF, Schwarting A, Knolle P, Meyer zum Buschenfelde KH, Mayet W. Effects of Th1 and Th2 cytokines on cytokine production and ICAM-1 expression on synovial fibroblasts. Ann Rheumatic Dis 1995; 54: 560-565.
74. Boughton-Smith NK, Evans SM, Hawkey CJ, Cole AT, Balsitis M, Whittle BJR, Moncada S. Nitric oxide synthase activity in ulcerative colitis and Crohn's disease. Lancet 1993; 342: 338-340.
75. Kolios G, Robertson DAF, Westwick J. Interleukin-13 regulates the nitric oxide production in human colonic epithelial cells. Comparison with interleukin-4 and interleukin-10. Gastroenterology 1996; 110: A940 (abstract).
76. Kucharzik T, Lugering N, Weigelt M, Adolf M, Domschke W, Stoll R. Comparison of the suppressive effects of interleukin-13, interleukin-10, and interleukin-4 on peripheral blood monocytes from patients with IBD. Gastroenterology 1996; 110: A943 (abstract).
77. Kucharzik T, Lugering N, Stoll R. Synergistic effect of immunoregulatory cytokines on peripheral blood monocytes: potential therapeutic approach in IBD? Gastroenterology 1996; 110: A943 (abstract).
78. Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med 1995; 181: 1373-1380.
79. Potten CS, Owen G, Hewitt D, Chadwick CA, Hendry H, Lord BI, Woolford LB. Stimulation and inhibition of proliferation in the small intestinal crypts of the mouse after in vivo administration of growth factors. Gut 1995; 36: 864-873.
80. Booth C, Evans GS, Potten CS. Growth factor regulation of proliferation in primary cultures of small intestinal epithelium. In Vitro Cell Develop Biol 1995; 31: 234-243.
81. McCabe RP, Secrist H, Botney M, Egan M, Peters MG. Cytokine mRNA expression in intestine from normal and inflammatory bowel disease patients. Clin Immunol Immunopath 1993; 66: 52-58.
82. Babyatsky MW, Rossiter G, Podolsky DK. Expression of transforming growth factors α and β in colonic mucosa in inflammatory bowel disease. Gastroenterology 1996; 110: 975-984.
83. Turner M, Chantry C, Katsidis P. Induction of the interleukin-1 receptor antagonist protein by transforming growth factor-β. Eur J Immunol 1991; 21: 1635-1639.
84. Vodovotz Y, Bogdan C, Paik J, Xie Q, Nathan C. Mechanisms of suppression of macrophage nitric oxide release by transforming growth factor β. J Exp Med 1993; 178: 605-613.
85. Gamble JR, Khew-Goodall Y, Vadas MA. Transforming growth factor-β inhibits E-selectin expression on human endothelial cells. J Immunol 1993; 150: 4494-4503.
86. 1 knockout mice: a mutation in one cytokine gene causes a dramatic inflammatory disease. Am J Pathol 1993; 143: 3-9.